Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVL-3288 in Schizophrenia and Schizoaffective Disorder
NCT02978599Phase 1Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Nov 2016
- Primary completion
- Oct 2018
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AVL-3288 in schizophrenia and schizoaffective disorder (3 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: Repeatable Battery for the Assessment of Neuropsychological Status Total Scale at 5 days. Started Nov 2016; status: completed.
02
Drugs
AVL-3288
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02978599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978599.